ScholarIQanswers from OpenAlex & ORCID
José Luis Górriz
ResearcherPublications, citations & collaboration network
José Luis Górriz is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does José Luis Górriz have?
ScholarIQindexed works
José Luis Górriz has 350 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does José Luis Górriz have?
ScholarIQcitation count
José Luis Górriz has 7,845 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of José Luis Górriz?
ScholarIQh-index
José Luis Górriz has an h-index of 44 in OpenAlex.
What is the i10-index of José Luis Górriz?
ScholarIQi10-index
José Luis Górriz has an i10-index of 147 in OpenAlex.
What is the ORCID of José Luis Górriz?
ScholarIQorcid
The ORCID for José Luis Górriz is on the source record.
What is the OpenAlex record for José Luis Górriz?
ScholarIQopenalex
The OpenAlex for José Luis Górriz is on the source record.
What are the most-cited papers on José Luis Górriz?
ScholarIQmost cited works
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Juan José Gorgojo Martínez, Pedro Mezquita‐Raya, Juana Carretero‐Gómez, Almudena Castro, Ana María Cebrián Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz, Miguel A. Rubio
Proteinuria: detection and role in native renal disease progression
José Luis Górriz, Alberto Martínez‐Castelao
Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study
José Luis Fernández Martín, Pablo Martínez‐Camblor, María Paula Dionisi, Jürgen Floege, Markus Ketteler, Gérard M. London, Francesco Locatelli, José Luis Górriz, Boleslaw Rutkowski, Aníbal Ferreira, Willem Jan W. Bos, Adrian Covic, Minerva Rodríguez-García, José Emilio Hernández Sánchez, Diego Rodrı́guez-Puyol, Jorge B. Cannata‐Andía
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
David C. Wheeler, Bergur V. Stefánsson, М. М. Батюшин, Oleksandr Bilchenko, David Z.I. Cherney, Glenn M. Chertow, Walter Douthat, Jamie P. Dwyer, Elizabeth Escudero, Roberto Pecoits‐Filho, Hans Furuland, José Luis Górriz, Tom Greene, Hermann Haller, Fan Fan Hou, Shin‐Wook Kang, Rey Isidto, Dinesh Khullar, Patrick B. Mark, John J.V. McMurray, Naoki Kashihara, Michał Nowicki, Frederik Persson, Ricardo Correa‐Rotter, Peter Rossing, Robert D. Toto, Kausik Umanath, Pham Van Bui, István Wittmann, Magnus Lindberg, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink
Diabetic kidney disease: from physiology to therapeutics
Carmen Mora‐Fernández, V. Domínguez-Pimentel, Mercedes Muros de Fuentes, José Luis Górriz, Alberto Martínez‐Castelao, Juan F. Navarro‐González